Compare AbbVie Inc (ABBV) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs McCormick & Company, Incorporated — how do they compare? AbbVie Inc trades at $254.11 (market cap $449.91B), while McCormick & Company, Incorporated trades at $51.93 (market cap $14.04B). The key difference: AbbVie Inc is far larger — about 32× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| ABBV | MKC | |
|---|---|---|
Market Cap | $449.91B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $72.90 |
52-Week Low | $184.85 | $45.60 |
Enterprise Value | $513.38B | $18.64B |
Dividend Yield | 2.72% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
McCormick (MKC) trades at $52.22, down 2.3% today but maintains a bullish technical outlook with strong support at $51. The company delivered solid Q2 2026 results with earnings of $0.80 per share beating estimates, driven by 14% constant currency sales growth and margin expansion to 40.2%. Valuation metrics appear attractive with a P/E of 8.62 and P/S of 1.89, while analyst consensus targets $59.67 representing 14% upside potential.
The investment case centers on MKC's defensive positioning in consumer staples, transformative Unilever food business combination potential, and improving profitability. Key risks include soft consumer volume trends in the Americas and execution challenges from the pending acquisition. With 36.7% of analysts rating the stock a buy and institutional ownership stable, MKC offers value with a 4% dividend yield amid ongoing operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
